Abbott Labs's most recent trend suggests a bullish bias. One trading opportunity on Abbott Labs is a Bull Put Spread using a strike $41.00 short put and a strike $36.00 long put offers a potential 5.04% return on risk over the next 29 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $41.00 by expiration. The full premium credit of $0.24 would be kept by the premium seller. The risk of $4.76 would be incurred if the stock dropped below the $36.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Abbott Labs is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Abbott Labs is bullish.
The RSI indicator is at 50.62 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Abbott Labs
Here's what companies were saying about the economy this week
Fri, 24 Oct 2014 14:16:10 GMT
Abbott Laboratories (ABT) Earnings Report: Q3 2014 Conference Call Transcript
Thu, 23 Oct 2014 15:57:00 GMT
[$$] Abbott Sales Rise 5.8%; Mylan Terms Revised
Thu, 23 Oct 2014 04:51:25 GMT
The Wall Street Journal – Abbott tweaked the terms of its agreement to sell a portion of its generic-drugs business to Mylan for $5.3 billion, signaling the deal will be completed despite new Treasury department rules.
Biogen, Thermo Reports Disappoint; Abbott Accelerates
Wed, 22 Oct 2014 22:43:00 GMT
Abbott, Mylan silent on why changing tax-inversion terms
Wed, 22 Oct 2014 22:22:06 GMT
Reuters – Drugmakers Abbott Laboratories and Mylan Inc on Wednesday declined to explain in detail why they changed the terms of a $5.3 billion deal in which Mylan will buy part of Abbott's overseas generics business and reincorporate for tax purposes in the Netherlands. The altered contract for the deal came a month after the Treasury Department made changes to U.S. “The (tax law) changes from Treasury are making people re-look at deal terms, and deals are not as favorable now,” said Edward Jones analyst Jeff Windau. Windau said many investors had feared the new Treasury rules might derail the deal, and they took comfort in statements by both Abbott and Pittsburgh-based Mylan on Wednesday that the transaction would go through in the first quarter of 2015.
Also on Market Tamer…
Follow Us on Facebook